secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2026-08-10T20:10:39+00:00
Accession:  0001193125-26-342388
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi Q2 2026: $120.7M cash, IND for MGX-001 hemophilia A on track for 4Q 2026
--------------------------------------------------------------------------------

- Cash, equivalents, and marketable securities $120.7M as of June 30, 2026; runway through 4Q 2027.
- IND application for MGX-001 (hemophilia A) on track for 4Q 2026; IND-enabling studies expected complete by end of Q3 2026.
- R&D expenses flat at $22.5M YoY; G&A down to $6.0M from $7.0M in Q2 2025.
- Two scientific posters won Top Poster Awards at 2026 ISTH Congress in Paris.
- Plans to initiate clinical trials in 2027 subject to regulatory clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526342388/0001193125-26-342388-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526342388/mgx-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342388

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer